A Phase II/III trial of JR-031 for the treatment of steroid-refractory acute Graft-versus-Host disease after hematopoietic stem cell transplantion

Trial Profile

A Phase II/III trial of JR-031 for the treatment of steroid-refractory acute Graft-versus-Host disease after hematopoietic stem cell transplantion

Completed
Phase of Trial: Phase II/III

Latest Information Update: 01 Feb 2016

At a glance

  • Drugs Remestemcel-L (Primary)
  • Indications Graft-versus-host disease
  • Focus Registrational; Therapeutic Use
  • Sponsors JCR Pharmaceuticals
  • Most Recent Events

    • 04 Sep 2015 According to Mesoblast media release, the Committee on Regenerative Medicine Products and Biological Technology of Pharmaceutical Affairs and Food Sanitation Council of the Japan Ministry of Health, Labour and Welfare has recommended for approval the allogeneic mesenchymal stem cell-based regenerative medicine product JR-031 (remestemcel-L).
    • 05 Jun 2014 Status changed from active, no longer recruiting to completed as reported by University Hospital Medical Information Network - Japan.
    • 22 Nov 2012 Actual initiation date changed from 1 Jan 2012 to 1 Nov 2011 as reported by University Hospital Medical Information Network - Japan.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top